The CCL2–CCR2 signaling axis has been implicated in many inflammatory and neurodegenerative diseases, such as atherosclerosis, multiple sclerosis, asthma, neuropathic pain, and diabetic nephropathy (O’Connor et al., 2015); therefore, it has also been explored as a potential target for the treatment of these diseases. This evidence concerns the gene CCR2 and asthma.